Antibiotic-resistant gut infections in young children represent one of the most pressing but underquantified threats to child survival in the developing world. A newly published multicountry surveillance effort directly confronts this gap, generating precisely the epidemiological data needed to design and deploy vaccines before resistance renders current treatment protocols obsolete.
The Enterics for Global Health (EFGH) study enrolled children aged 6–35 months presenting with acute diarrhea across seven low- and middle-income countries — Kenya, Malawi, Mali, The Gambia, Bangladesh, Pakistan, and Peru — between June 2022 and August 2024. Using both microbiological culture and quantitative PCR (qPCR) targeting the ipaH virulence gene (cycle threshold ≤29.5), the study established care-seeking–adjusted incidence estimates for Shigella-attributable diarrhea alongside serotype distribution and disc-diffusion–based antimicrobial resistance profiles. This dual-detection approach increases sensitivity beyond what culture alone captures, addressing a longstanding underestimation problem in enteric disease surveillance.
The findings arrive at a pivotal moment. Multiple Shigella vaccine candidates are in late-stage development, and understanding which serotypes predominate across geographies — and how resistance patterns vary — is essential for antigen selection and prioritization decisions. Beyond mortality, Shigella infection in this age window is linked to environmental enteric dysfunction and linear growth stunting, compounding its public health impact far beyond acute illness episodes. The study's hybrid facility-based design, correcting for care-seeking behavior through a concurrent health-utilization survey, represents a methodological advance over passive surveillance. Key limitations include the facility-based frame, which may miss severe cases that never reach care, and the relatively short surveillance window. Still, this is one of the most geographically comprehensive prospective Shigella burden studies to date, and its data will likely directly inform WHO vaccine target product profiles and national immunization program planning across the highest-burden regions.